التداخل بين إيفيروليموس وتولفابتان

…dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS [see Warnings and Precautions (5.2) ] Unable to sense or respond to thirst Hypovolemic hyponatremia Taking strong CYP3A inhibitors [see Warnings and Precautions (5.5) ] Anuria Hypersensitivity (e.g., anaphylactic shock, rash generalized) to tolvaptan or any components of the product [see Adverse…

Concomitant use of strong CYP3A inhibitors ( 4 )

Avoid use with moderate to strong CYP3A inhibitors ( 5.5 )

Do not use SAMSCA with strong inhibitors of CYP3A [see Contraindications (4) ] and avoid concomitant use with moderate CYP3A inhibitors.

Avoid concomitant use with: Moderate CYP3A inhibitors ( 7.1 )